Stem cell transplantation (SCT) may be the only curative option for patients with relapsed or refractory leukaemia, that is, high-risk (HR) leukaemia. Several salvage regimens have been used to cytoreduce disease before SCT, but disease progression or treatment toxicity limits numbers of patients receiving SCT. Here, we report our experience with high-dose cytarabine and amsacrine (Araamsa) to salvage patients with HR-leukaemia in the context of SCT. A total of 34 patients with HR-leukaemia (20 AML, 12 ALL, two advanced CML) received 3 g/m 2 / day cytarabine for 5 days and amsacrine 200 mg/m 2 /day for 3 days. Disease response was observed in 62% of patients. Toxicity was limited to neutropenic fever, one patient developed cerebellar toxicity and there was one treatment-related death. A total of 17 patients proceeded to SCT (12 allografts and five autografts). Median survival (OS) of all patients was 10.8 months (95% CI 7.8-21). Patients who were consolidated with SCT after salvage therapy had a superior median OS of 29.4 months (95% CI 12.5-upper limit not reached, n ¼ 17) than those who did not receive SCT (6.7 months, CI 1.5-8.6, Po0.0001). Median disease-free survival with SCT (23 months) was higher than after treatment with salvage chemotherapy alone (6.7 months, P ¼ 0.0002). Thus Araamsa can be used effectively to salvage HR-leukaemia, enabling further consolidation with SCT. Bone Marrow Transplantation (2003Transplantation ( ) 32, 273-278. doi:10.1038 Keywords: salvage treatment; transplantation; high-risk leukaemia; relapse; refractory Disease relapse after chemotherapy is common in adults with acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) and 5-year survival in patients treated with chemotherapy alone is unsatisfactory.
leukaemia; relapse; refractory Disease relapse after chemotherapy is common in adults with acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) and 5-year survival in patients treated with chemotherapy alone is unsatisfactory. 1, 2 Disease-free survival (DFS) is even poorer in patients developing the blastic phase of chronic myeloid leukaemia (CML) 3 and those with myelodysplastic syndromes (MDS), 4 and it is common for the disease to be refractory to standard chemotherapy. Attempts have been made to risk stratify patients at diagnosis based on characteristic cytogenetic or molecular markers that predict disease response to treatment, so that those with an increased probability of relapse, that is, high-risk (HR) leukaemia may be treated more intensively after induction or consolidation therapy. 5, 6 Nevertheless, a large proportion of patients with HR disease continue to be identified by a failure to respond to standard induction chemotherapy (refractory leukaemia) or disease recurrence following complete remission (CR).
A number of salvage chemotherapeutic regimens have been developed in the last 15 years to improve outcomes in patients with HR-leukaemia. [7] [8] [9] [10] Most regimens contain cytarabine (Ara-C) at low, intermediate or high doses, along with daunorubicin, amsacrine (amsa), etoposide, mitoxantrone or fludarabine. Although randomised studies comparing the ability of these different regimens to induce CR are lacking, the proportion of patients who achieve remission, the duration of remission and overall survival (OS) appear to be similar in different reports. While response rates (CR2) of up to 89% can be achieved in patients with AML in first relapse with different chemotherapy regimens, median survival is only 12 months. 10 In an attempt to improve long-term outcome in patients with HR-leukaemia, stem cell transplantation (SCT) with an allograft or autograft is the favoured approach, depending on age, performance status and availability of a suitable donor. 11, 12 Disease relapse, nevertheless, remains a problem even after SCT. It has been suggested that posttransplant outcome may depend on disease status at the time of SCT, 12, 13 and that patients in haematological remission at the time of transplant have superior DFS and OS. Thus, in an attempt to improve post-transplant outcomes, 'salvage' regimens have been used to reduce the leukaemic cell burden prior to SCT.
In this study, we have retrospectively examined the use of high-dose Ara-C and amsacrine (Ara-amsa) as a salvage regimen in patients with HR-leukaemia treated at the two participating centres. The use of Ara-amsa to salvage refractory or relapsed leukaemia was described over 14 years ago 7 and this regimen is used extensively in different centres. Nevertheless, there are not many reports on outcomes of patients with HR-leukaemia salvaged with Ara-amsa prior to consolidation with SCT. Here, we have studied the efficacy and toxicity of Ara-amsa in the context of SCT, and have compared our results with those reported with the use of other salvage regimens prior to transplantation.
Patients and methods

Patients
Data on patients with HR-leukaemia treated with Araamsa between 1987 and 2001 at the two centres participating in this study were reviewed retrospectively. Patients were classed as having HR-disease if they failed to enter CR after two or more courses of induction therapy (primary refractory disease), had relapsed disease after initial CR1 with standard induction treatment or if there was a myeloproliferative disorder or myelodysplastic syndrome preceding the onset of acute leukaemia. Morphological, immunophenotypic and cytogenetic analysis of bone marrow was performed in all cases at diagnosis as well as to assess response to treatment.
CR was defined by the presence of a blast cell population of less than 5% of marrow nucleated cells in the presence of morphologically normal trilineage haemopoiesis in the marrow. Disease relapse was diagnosed by the re-emergence of blasts (45%) in the marrow after an initial CR. The presence of X5% but o30% blasts in the marrow after treatment indicated partial remission (PR), and patients with persistent myelodysplasia despite the presence of less than 5% blasts were regarded as having refractory disease.
Schedule of salvage regimen
Patients with HR-leukaemia were treated with amsacrine 200 mg/m 2 daily for 3 days and, concurrently, 3 g/m 2 Ara-C once daily for 5 days. Adjustments in dosage were made if patients had impaired hepatic or renal function. Amsacrine was infused over 45 min and Ara-C was administered over 3 h, with a gap of 24 h between successive doses. Ophthalmic solution of prednisolone (0.5%) was instilled in both eyes every 2 h from day 1 of treatment until 5 days after completion of chemotherapy, as prophylaxis against Ara-C-induced conjunctivitis.
Transplantation after salvage chemotherapy
Following treatment with Ara-amsa, patients with an available HLA-matched sibling or unrelated donor received an allograft if they were less than 55 years old with good performance status. An autograft was performed in patients who were less than 70 years old, with good performance status, but not eligible for an allograft. Time to transplantation was calculated from the date of salvage therapy.
End points
Duration of survival (OS) and DFS were the end points of the study. OS was measured from the time interval between the date of salvage with Ara-amsa until the date of death or last follow-up. DFS was calculated from the date of Araamsa to the date of relapse (for patients who achieved CR after salvage therapy), death from any cause or last followup for survivors. Treatment-related mortality (TRM) was defined as death occurring in patients in continuing CR.
Statistical methods
Survival curves were constructed using the method of Kaplan and Meier and the log-rank test was used to assess differences between groups. Data were analysed using the statistical software SAS (SAS Institute, SAS Circle, North Carolina, USA).
Results
Patient details
A total of 34 patients with HR-leukaemia were treated with high-dose Ara-C and amsacrine between 1987 and 2001. Patient characteristics are shown in Table 1 . There were 20 males and 14 females with a median age of 28 years (range 18-63). A total of 12 patients were diagnosed with ALL, 20 with AML (including AML M3, HR-MDS and secondary leukaemia) and two patients with accelerated phase and lymphoid blast transformation of CML, respectively. Cytogenetic abnormalities were detected in 16 patients with AML (including t(15;17) in AML M3) and five patients with ALL (Table 1) . One patient had relapsed after an autograft (no. 17), while another (no. 21) with recurrence of ALL had previously received two allografts. All newly diagnosed patients received induction chemotherapy in the context of the Medical Research Council (MRC), UK led multicentre clinical trials (Table 1 ).
Response to induction therapy
A total of 33 patients were treated with primary induction chemotherapy; one with MDS/sAML (no. 7) had received only blood product support. Of the 33 treated patients, 23 (70%) had responsive disease (22 CR +1 PR) and 10 (30%) had primary refractory leukaemia ( Table 2 ). All patients with ALL had chemosensitive disease (11 CR and 1 PR), eight patients with AML were refractory to induction chemotherapy. Both patients with advanced CML also had refractory disease. The median duration to relapse from last CR was 29 months (range 1-89). The two patients who had relapsed after previous SCT (nos. 17 and 21) had been in CR for 89 months (post autograft) and 35 months (post allograft), respectively.
Response to salvage therapy
Following treatment with Ara-amsa, 19/34 (56%) achieved CR while two patients entered PR (Table 2) . Of these patients with chemoresponsive disease, Ara-amsa had been Salvage therapy and transplantation in high-risk leukaemia S Tauro et al used as a second-line salvage therapy owing to failure of FLAG and doxorubicin, cytarabine and thioguanine (DAT) in one patient (no. 12), cytarabine, doxorubicin and etoposide (ADE) and ATRA in another (no. 3) and phase I induction of UKALL X in a third patient (no. 15). A total of 14 patients were treated with two courses of salvage chemotherapy: 10/14 attained CR after one course, one after two courses and three patients had refractory disease. Of the patients with disease response to Ara-amsa, 12 had AML (four with primary refractory disease and eight patients in first relapse), eight had ALL and one had been diagnosed as CML in lymphoid blast crisis. Thus, 62% of all patients (60% of those with AML and 67% of ALL) exhibited a response to Ara-amsa, but 13 patients (38%), including five with primary refractory leukaemia, were refractory to salvage treatment.
Toxicity
Pyrexial episodes (X381C equivalent to a WHO toxicity of Xgrade 2) were a common occurrence in all patients. Culture-positive fevers were, however, uncommon, although Streptococcus causing meningoencephalitis, and sepsis from pseudomonas and enterococcus (VRE) were identified in three patients. Nonhaematological toxicity included cerebellar toxicity (no. 26) and one patient each had drug-rash and nephrotoxicity. The dose of Ara-amsa had to be reduced by half and one-third in two patients, respectively, (nos. 2 and 18) during their second course of salvage treatment. One patient died in remission within 2 months of receiving salvage treatment (TRM), although the definitive cause of death could not be established.
Further treatment
After salvage therapy, two patients with chemoresponsive disease (nos. 1 and 4) were consolidated further with phase 1 induction chemotherapy of UKALL 12, along with intrathecal methotrexate, whereas one patient (no. 9) was treated with phase 2 induction (UKALL 12). These patients subsequently proceeded to SCT. One patient (no. 18) had a short-lived CR post-Ara-amsa (5 months), but was successfully reinduced with FLAG-idarubicin, achieved CR with and proceeded to SCT. Other patients with refractory disease, however failed to respond to second salvage with ADE (nos. 7 and 13) or FLAG (nos. 6, 11 and 25).
A total of 17 patients (50% of those treated with the salvage regimen) proceeded to SCT with an allograft or autograft (Table 2) . These included 10 patients with AML and seven patients with ALL. A total of 12 patients Salvage therapy and transplantation in high-risk leukaemia S Tauro et al received an allograft: six from an HLA-matched sibling and six from an unrelated donor (four AML and one ALL). The remaining five patients were treated with autologous transplantation. The median time to SCT was 4 months (range 2-10) from the date of salvage therapy (date of first cycle in patients who received two). Details of conditioning regimens used for pretransplant conditioning are shown in Table 3 . Two patients had refractory disease (with normal blood counts) at the time of myeloablative therapy: one received an allograft and the other, an autograft. Of the patients not treated with SCT, 11 had refractory or relapsed disease after Ara-amsa, three did not have autologous stem cells or a stem cell donor and one had previously received a sibling allograft on two occasions. One patient declined treatment with SCT, while another died in CR (TRM).
Outcomes
With a mean follow-up of 18.5 months (range 1-76 months, median 10 months), the median survival (OS) of all patients treated with salvage chemotherapy was 10.8 (95% CI Salvage therapy and transplantation in high-risk leukaemia S Tauro et al 7.8-21). Disease relapse accounted for death in the majority of patients ( Table 2 ). The median OS of patients treated with SCT (including those with refractory disease) was 29.4 months (95% CI 12.5-upper limit not reached) with an expected 3-year survival of 48.4% and this was significantly higher than in patients who did not receive an auto/ allograft (median 6.7 months, 95% CI 1.5-8.6 months, Po0.0001). Likewise, the expected 3-year survival in patients who did not receive further consolidation with SCT was 6.5% and this was significantly lower than in patients receiving an auto or allograft ( Figure 1 ). As with OS, patients receiving SCT had a longer DFS (23 months, 95% CI 12.5-upper limit not reached), compared to those not consolidated with salvage chemotherapy alone (P ¼ 0.0002). In the latter group of patients, the median DFS was identical to the OS. Numbers of patients with AML permitted a subgroup analysis: median OS in patients with chemosensitive HR-AML, that is, those who entered CR or PR after salvage with Ara-amsa, was 15.4 months (95% CI 9.0-upper limit not reached) compared with 8.8 months (95% CI 3.1-10.8, P ¼ 0.06) in those who were refractory to Ara-amsa ( Figure 2 ). Two of the three patients who received SCT despite a lack of disease response to Ara-amsa died of relapsed leukaemia post-SCT, but the benefit of SCT in prolonging OS in HR-AML nevertheless appeared to be maintained (data not shown).
Discussion
Allogeneic or autologous transplantation may be the only curative option for eligible patients with relapsed or refractory leukaemia (HR-leukaemia). After transplantation, 3 year survival in patients with relapsed AML receiving an HLA-sibling allograft in CR2 is 44 and 38% after an autograft, while corresponding survival figures for relapsed ALL are 30 and 34%, respectively.
14 Since improved outcomes are observed in the absence of residual disease at the time of transplantation, 12,13 salvage regimens have been used to cytoreduce patients with HR disease prior to an auto or allograft. While response rates in HRleukaemia have undoubtedly improved with the use of high-intensity salvage regimens, there is significant toxicity associated with many of these regimens. Furthermore, not many eligible patients reach the stage of SCT because of the short duration of remission.
In our study, the response rates after Ara-amsa in HR-AML (62%) and toxicity are similar to those reported previously: combinations of high-dose Ara-C and amsacrine or mitoxantrone have been reported to induce remissions in up to 50% of patients with relapsed or refractory AML, 15 although treatment-related deaths were reported in 6/52 patients. With the GEMIA protocol, 16 12 out of 20 patients with HR-AML were able to achieve CR, although five other patients died of infectious complications. CR rates of 45% have also been achieved with timedsequential chemotherapy (EMA-86 TSC) 17 although a significant toxic risk is associated with its use. Recent interest has focused on the use of FLAG, with CR rates of up to 48% in patients with relapsed and refractory AML and de novo RAEB-t reported in a large series. 18 In patients with HR-ALL, the observed response rates of up to 67% with Ara-amsa are comparable to those reported with the use of multiphase reinduction salvage regimens in patients with relapsed or refractory ALL (62%). 19 Our remission rates are less impressive than those reported by Martino et al 20, 21 (78% CR) with the use of a combination chemotherapy (intermediate-dose Ara-C, vindesine, mitoxantrone, cyclophosphamide, prednisolone and methotrexate). Nevertheless, the proportion of HR-ALL patients who proceeded to SCT in the study described by Martino et al (RELAL-88) was similar to that observed after the use of Ara-amsa in our series.
The ability to consolidate patients with SCT following salvage with Ara-amsa was in part due to the relatively low toxicity of the salvage regimen. Although neutropenic fever was a common occurrence, one patient developed self-limiting cerebellar toxicity and there was only one treatment-related death. Thus, up to 50% of patients (10/12 with HR-AML and 7/12 with HR-ALL) were able to proceed to SCT. In contrast, only five out of 14 patients in CR proceeded to SCT in the GEMIA study 16 and 10/61 patients were able to receive consolidation with SCT after Months from Ara-amsa salvage with a combination of idarubicin and intermediatedose Ara-C. 22 The ability to treat a larger proportion of patients with SCT with the use of FLAG as a salvage regimen has been recently demonstrated, 23 although results from larger studies are awaited.
Not surprisingly, the improved survival after Ara-amsa appears to be related to further treatment with SCT (auto or allograft) with 3-year-survival figures approaching 50%. These compare favourably with survival values from transplant registries, and are similar to those observed after salvage chemotherapy with regimens containing mitoxantrone 24 or idarubicin 25 along with Ara-C and etoposide, followed by SCT. Nevertheless, additional approaches to optimise the antileukaemic effect are required not only for patients who are not candidates for myeloablative therapy, but also for those with disease relapse following SCT.
